OTQ923 (trial: phase I/II; regulatory status: investigational): One of the most precise and promising gene editing strategies in development for SCD is direct correction of the causative HBB mutation using CRISPR/Cas9. This evidence concerns the gene HBB and Schnyder corneal dystrophy.